is the fourth most prevalent cancer and the second most common cause of cancer-related deaths throughout the world (Sang, 2012; Schwarz and Smith, 2007; Jemal et al.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gastric cancer
technologies and products.
pylori eradication therapy in preventing gastric cancer
in healthy asymptomatic infected individuals (risk ratio, 0.
Conclusion: The current study strongly reveals that rosamultic acid inhibits gastric cancer
proliferation by inducing apoptosis mediated through cell cycle arrest, downregulation of cell cycle related protein expressions, inhibition of cell migration, DNA damage, and activation of caspases.
From a total of 130 volatile chemicals, eight showed levels that were distinctly different in the gastric cancer
group compared with those with only pre-cancerous changes.
Since fatty acids of Omega 3, 6, 9 plays a role in inflammation and inflammation is among the main factors of apoptosis activation, so using a food diet containing fatty acids of Omega 3, 6, 9 along with chemotherapy will increase the efficiency of chemotherapy in patients with gastric cancer
, if it activates apoptosis .
It was found that denerving the vagus nerve through botox injections had the same effect as vagotomy that helped block the development of gastric cancer
in the mice.
Also, immigrants born in Asian and former USSR countries had higher risks of developing gastric cancer
We studied a cohort of 412 gastric cancer
patients who underwent gastrectomy with lymph node dissection at Pusan National University Hospital between 2005 and 2007.
has been shown to be influenced by many factors, no single factor being identified as being causal,  though Helicobacter pylori infection is a dominant permissive factor.
For every 20 patients with Helicobacter pylori infection, one case of gastric cancer
was prevented when the bacterium was eradicated.
Genta Incorporated (GNTA), Berkeley Heights, has announced results from the company's Phase 2, confirmatory, clinical trial of tesetaxel as 2nd-line treatment of patients with advanced gastric cancer
Researchers develop non-invasive test for gastric cancer
is the fourth most common cancer and the second leading cause of cancer-related deaths following lung carcinoma despite a worldwide decline in both its incidence and mortality since the late half of the twentieth century (1,2).
Two new cancer treatments have been approved for NHS patients: capecitabine for advanced gastric cancer
and gefitinib for metastatic non-small-cell lung cancer.